1000787-43-8

Basic information

• Product Name: 5-bromo-2-(methoxymethyl)Pyridine
• Synonyms: 5-bromo-2-(methoxymethyl)Pyridine
• CAS NO: 1000787-43-8
• Molecular Formula: C7H8BrNO
• Molecular Weight: 202.04852
• Mol File: 1000787-43-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 214.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.463±0.06 g/cm3(Predicted)
• PKA: 1.94±0.22(Predicted)
• CAS DataBase Reference: 5-bromo-2-(methoxymethyl)Pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(methoxymethyl)Pyridine(1000787-43-8)
• EPA Substance Registry System: 5-bromo-2-(methoxymethyl)Pyridine(1000787-43-8)

Safety Data

• Hazardous Substances Data: 1000787-43-8(Hazardous Substances Data)

Upstream product

• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 88139-91-7 (5-bromopyridin-2-yl)methanol 
• 74-88-4 methyl iodide 

Downstream Products

• 1615739-76-8 (6-(methoxymethyl)pyridin-3-yl)boronic acid 
• 2088113-98-6 6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide 
• 1430401-34-5 2-(methoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 

Relevant articles and documents

QUINOLINO-PYRROLIDIN-2-ONE DERIVATIVE AND APPLICATION THEREOF

Disclosed are a series of quinolino-pyrrolidin-2-one compounds, and application thereof in preparation of drugs for ATM inhibitor-related diseases. The present disclosure specifically relates to a derivative compound represented by formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.

Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase

A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide (72) and 7-fluoro-6-[6-(methoxymethyl)pyridin-3-yl]-4-{[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino}quinoline-3-carboxamide (74) as potent and highly selective ATM inhibitors with overall ADME properties suitable for oral administration. 72 and 74 constitute excellent oral tools to probe ATM inhibition in vivo. Efficacy in combination with the DSB-inducing agent irinotecan was observed in a disease relevant model.

1,4-PYRIDONE COMPOUNDS

The present invention relates to 1,4-pyridone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.